Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE versus WESTADONE.
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semisynthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Homatropine methylbromide is an anticholinergic agent that reduces gastrointestinal motility and secretions.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Oral: 5 mg hydrocodone/1.5 mg homatropine every 4 to 6 hours as needed; maximum 30 mg hydrocodone per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
The terminal elimination half-life of hydrocodone is approximately 3.8-4.5 hours in adults, though it may be prolonged in hepatic impairment or elderly patients. Homatropine methylbromide has a half-life of about 2-3 hours.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Hydrocodone and its metabolites are primarily excreted renally. Approximately 60% of a dose is eliminated in urine as unchanged drug and conjugates, with less than 5% excreted in feces. Homatropine methylbromide is a quaternary ammonium compound that is poorly absorbed and excreted mainly unchanged in feces via biliary elimination.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist